Subvariants BQ.1 and BQ.1.1, which became the nation’s most pervasive strains in November, are on the decline.
The FDA began tracking XBB on Nov. 28. The subvariant is a fusion of two other omicron subvariants, BA.2.10.1 and BA.2.75, and it caused a wave of cases in Singapore. Eric Topol, MD, founder and director of Scripps Research Translational Institute in San Diego, wrote Dec. 23 that XBB mutation XBB.1.5 “has the most growth advantage vs. BA.5,” which was causing most COVID-19 cases for months.
The tweaked booster shots are expected to have some protection against XBB and XBB.1.5, Dr. Topol wrote. However, Anthony Fauci, MD, outgoing director of the National Institute of Allergy and Infectious Diseases, said in late November, “The protection is diminished multifold with XBB.”
Two more COVID-19 updates:
1. Hospitalizations: The daily average for new hospital admissions on Dec. 26 was 40,156, according to The New York Times.
2. Deaths: From Dec. 16-23, 2,952 people died from COVID-19, according to HHS. As of Dec. 14, the latest CDC data available, a total of 1,083,279 COVID-19 deaths have been reported in the United States.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
